Skip to main content
ENTA
NASDAQ Life Sciences

Enanta Pharmaceuticals Reports Strong Q1 Financials and Advances Multiple Clinical Programs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$14.73
Mkt Cap
$401.326M
52W Low
$4.09
52W High
$17.15
52W Position info
260% above low
Off High info
14% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ENTA has more than doubled off its 52-week low of $4.09.

Summary

Enanta Pharmaceuticals reported a significantly reduced net loss for Q1 2026 and extended its cash runway into fiscal 2029, while also advancing its lead RSV candidate towards Phase 3 and introducing new immunology programs with upcoming IND filings.


Key Events · Earnings and Guidance · ENTA

  • Reduced Net Loss

    Reported a net loss of $11.9 million ($0.42/share) for Q1 2026, a significant improvement from $22.3 million ($1.05/share) in Q1 2025.

  • Extended Cash Runway

    Maintained a strong financial position with $241.9 million in cash and marketable securities, projecting a cash runway into fiscal 2029.

  • RSV Program Advancement

    Progressed zelicapavir, its lead RSV candidate, towards Phase 3 discussions with the FDA, targeting alignment in Q2 2026.

  • New Immunology Program Introduced

    Announced a third immunology program targeting MRGPRX2 inhibition, with a development candidate selection expected in the second half of 2026.


Analysis · ENTA · Life Sciences

Enanta Pharmaceuticals delivered a robust quarterly update, showcasing significant financial improvements and substantial progress across its clinical pipeline. The company's ability to nearly halve its net loss year-over-year, coupled with a strong cash position that extends its operational runway into fiscal 2029, provides a solid foundation for its development efforts. Strategically, the advancement of zelicapavir towards Phase 3 discussions for RSV treatment is a critical milestone, potentially positioning it as a first-in-disease therapy. Furthermore, the expansion of its immunology portfolio with a new MRGPRX2 program and clear timelines for IND filings and Phase 1 data for its KIT and STAT6 inhibitors demonstrate active and promising R&D. Investors should monitor the upcoming FDA alignment for zelicapavir's Phase 3 trial and the planned IND submissions for the immunology candidates as key catalysts.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENTA was trading at $14.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $401.3M. The 52-week trading range was $4.09 to $17.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENTA - Latest Insights

ENTA
Nov 16, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.41
Real-time Price: $8.99 info
Change: -$1.42 (-14%) info
Market Cap: $253.1M info
ENTA
Nov 16, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.66
Real-time Price: $8.99 info
Change: -$1.67 (-16%) info
Market Cap: $253.1M info
ENTA
Oct 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.15
Real-time Price: $8.99 info
Change: -$2.16 (-19%) info
Market Cap: $253.1M info
ENTA
Oct 28, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.99
Real-time Price: $8.99 info
Change: -$3.00 (-25%) info
Market Cap: $253.1M info
ENTA
Aug 12, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $13.52
Real-time Price: $8.99 info
Change: -$4.53 (-34%) info
Market Cap: $253.1M info